Your browser doesn't support javascript.
loading
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A; Zijlstra, Josée M; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kühnhardt, Dagmar; Ostermann, Helmut; Schmitz, Norbert; Hertenstein, Bernd; Aulitzky, Walter; Maschmeyer, Georg; Vieler, Tom; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Kuhnert, Georg; Diehl, Volker; Dietlein, Markus; Engert, Andreas.
Afiliación
  • Borchmann P; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany. Electronic address: peter.borchmann@uni-koeln.de.
  • Goergen H; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
  • Kobe C; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
  • Lohri A; Cantonal Hospital Baselland, Liestal, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland.
  • Greil R; IIIrd Medical Department, Paracelcus Medical University and Salzburg Cancer Research Institute, Salzburg, Austria; Salzburg Cancer Research Institute and AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie), Salzburg, Austria.
  • Eichenauer DA; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
  • Zijlstra JM; VU University Medical Center, Amsterdam, Netherlands.
  • Markova J; Department of Internal Medicine-Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Meissner J; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Feuring-Buske M; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
  • Hüttmann A; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany.
  • Dierlamm J; Department of Oncology and Haematology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Soekler M; Department of Oncology and Haematology, University of Tübingen, Tübingen, Germany.
  • Beck HJ; Department of Oncology and Haematology, University Hospital Mainz, Mainz, Germany.
  • Willenbacher W; Salzburg Cancer Research Institute and AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie), Salzburg, Austria; Medical University Innsbruck, Internal Medicine V: Hematology & Oncology, Innsbruck, Austria; Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria.
  • Ludwig WD; HELIOS Medical Center Berlin-Buch, Berlin, Germany.
  • Pabst T; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Department of Medical Oncology, Inselspital Bern, Bern, Switzerland.
  • Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Hitz F; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Cantonal Hospital of St Gallen, St Gallen, Switzerland.
  • Bentz M; Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
  • Keller UB; Department of Internal Medicine III, Klinikum "Rechts der Isar", Munich, Germany.
  • Kühnhardt D; Department of Hematology and Oncology, Charité University of Medicine, Berlin, Germany.
  • Ostermann H; Department of Hematology/Oncology, University Hospital of Munich, Munich, Germany.
  • Schmitz N; Department of Haematology, Asklepios Hospital St Georg, Hamburg, Germany.
  • Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
  • Aulitzky W; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany.
  • Maschmeyer G; Department of Haematology, Oncology and Palliative Care, Ernst von Bergmann Hospital, Potsdam, Germany.
  • Vieler T; Karl Lennert-Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Eich H; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany.
  • Baues C; Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany.
  • Stein H; Berlin Reference Center for Lymphoma and Haematopathology, Berlin, Germany.
  • Fuchs M; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
  • Kuhnert G; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
  • Diehl V; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
  • Dietlein M; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
  • Engert A; German Hodgkin Study Group, Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany.
Lancet ; 390(10114): 2790-2802, 2017 12 23.
Article en En | MEDLINE | ID: mdl-29061295
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article